Atovaquone Production Cost Reports

The report provides a detailed analysis essential for establishing an atovaquone production plant. It encompasses all critical aspects necessary for atovaquone production, including the cost of atovaquone production, atovaquone plant cost, atovaquone production costs, and the overall atovaquone production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an atovaquone production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Atovaquone is an antiparasitic and antimicrobial medicine that is mainly used to treat and prevent serious infections. It is primarily utilised for the treatment and prevention of certain parasitic and fungal infections in people with weakened immune systems. It is also prescribed for the treatment of malaria caused by Plasmodium parasites, especially in combination with other drugs. It works by interfering with the energy production process of parasites and certain microorganisms, which stops their growth and survival.

It is also widely used for the prevention and treatment of Pneumocystis jirovecii pneumonia (PCP), which is a serious lung infection common in AIDS patients or those on immunosuppressive drugs. Moreover, it is also used in veterinary medicine to control protozoal diseases like babesiosis and toxoplasmosis in dogs, cats, and livestock. Additionally, it is often used in combination with other medications like Malarone for the management of specific opportunistic infections.

The primary factor that drives the demand for atovaquone is its demand as a synthetic antimicrobial drug in preventive care for the treatment of certain parasitic and protozoal infections. Its application as an antiprotozoal prescription medicine for the treatment of AIDS-associated Pneumocystis pneumonia (PCP) in adults and adolescents significantly promotes its demand in the pharmaceutical industry. Its usage as an antimalarial agent in combination with other medicines like proguanil for the treatment of Plasmodium falciparum malaria further supports its demand in the pharmaceutical and healthcare industries.

Its usage as a veterinary drug for the treatment of protozoal diseases in animals like dogs and cats also contributes to its demand in the veterinary and animal healthcare industries. Its demand as a reference drug in clinical trials for developing new combination therapies for resistant malaria strains also drives its market expansion. Moreover, factors such as the cost and availability of major raw materials, regulatory approvals, quality standards, and compliance with international health guidelines largely impact industrial atovaquone procurement.

The rising prevalence of infectious diseases in tropical and developing regions, along with increasing travel-related malaria cases, also contributes to its higher consumption. Manufacturing capabilities, supplier reliability, stable distribution networks, and efficient global logistics also play an important role in shaping the overall atovaquone market and its procurement strategies.

Raw Material for Atovaquone Production

According to the atovaquone production plant project report, the major raw materials for atovaquone production include cyclohexene, acetyl chloride, hypobromite, 2-chloro-1,4-naphthoquinone, and potassium hydroxide.

Production Process of Atovaquone

The extensive atovaquone production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of atovaquone begins with the preparation of 4-(4-chlorophenyl)cyclohexane-1-carboxylic acid, formed by reacting cyclohexene with acetyl chloride in the presence of aluminium chloride to obtain a substituted cyclohexyl ketone. Then, this ketone is converted to the corresponding carboxylic acid through hypobromite oxidation. Further, the acid intermediate is coupled with 2-chloro-1,4-naphthoquinone in the presence of a silver salt and an oxidising agent to construct the naphthoquinone framework. The resulting product is then treated with potassium hydroxide to complete hydrolysis and furnish the desired hydroxy-1,4-naphthoquinone structure. After purification and isolation, the process leads to the formation of atovaquone as the final product.

Atovaquone is a hydroxynaphthoquinone compound and a structural analogue of ubiquinone (coenzyme Q10), and it acts as an antiprotozoal mitochondrial electron transport inhibitor. It appears as a yellow to orange crystalline solid that is practically insoluble in water. The molecular formula of the compound is C22H19ClO3, and its molar mass is 366.84 g/mol. It has a density of approximately 1.349 g/cm³, and it is insoluble in water but soluble in organic solvents such as DMSO and tetrahydrofuran. The compound has a melting point in the range of 216-219 degrees Celsius, and its boiling point is approximately 535 degrees Celsius at 760 mmHg. It has a flash point of around 281.7 degrees Celsius. The compound is classified as environmentally hazardous, particularly toxic to aquatic organisms, and it is recommended to handle it with appropriate protective equipment and store it at -20 degrees Celsius. The compound may cause adverse effects such as gastrointestinal disturbances, headache, and rash.